AFMD Affimed N.V.

Affimed to Participate in Upcoming Investor Conferences

Affimed to Participate in Upcoming Investor Conferences

MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company’s management will participate in the following investor conferences during the month of November 2023.

Truist Securities BioPharma Symposium (November 8-9, 2023)

Date: Wednesday, November 8, 2023

One-on-one meetings only

Location: New York, NY

Jefferies London Healthcare Conference (November 14-16, 2023) 

Date: Wednesday, November 15, 2023

Presentation Time: 8:30 a.m. EST / 1:30 p.m. GMT / 14:30 CET

Location: London, UK

Webcast: 

For more information or to schedule a one-on-one meeting with Affimed’s management, please contact your event representative or Alex Fudukidis via email at or phone at +1 (917) 436-8102.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Mannheim, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: .

Investor Relations Contact

Alexander Fudukidis

Director, Investor Relations

E-Mail: 

Tel.: +1 (917) 436-8102



EN
01/11/2023

Underlying

AFMDAffimed N.V.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Affimed N.V.

 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Receipt of Nasdaq Delisting Notice

Affimed Announces Receipt of Nasdaq Delisting Notice MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 No...

May 14, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Announces Filing for the Opening of Insolvency Proceedings MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the “Company”) has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capita...

May 13, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Shows Higher Exposure of AFM24 is Associated with Significantl...

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve e...

April 29, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Acceptance of Three Abstracts for Presentation at th...

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinica...

April 23, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimu...

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed be...

April 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch